IN165717B
(fr)
*
|
1986-08-07 |
1989-12-23 |
Battelle Memorial Institute |
|
US5529932A
(en)
*
|
1988-01-28 |
1996-06-25 |
Pharmacia, S.P.A. |
Isolated DNA encoding a plant ribosome inactivating protein from the leaves of saponaria officinalis
|
IL106992A
(en)
*
|
1988-02-11 |
1994-06-24 |
Bristol Myers Squibb Co |
Noble hydrazonic history of anthracycline and methods for their preparation
|
DE4004573A1
(de)
*
|
1989-02-17 |
1990-08-23 |
Tanabe Seiyaku Co |
Neues versuchstier und seine herstellung
|
US5354844A
(en)
*
|
1989-03-16 |
1994-10-11 |
Boehringer Ingelheim International Gmbh |
Protein-polycation conjugates
|
US5191067A
(en)
*
|
1989-04-27 |
1993-03-02 |
The Salk Institute For Biological Studies |
Fibroblast growth factor conjugates
|
US5576288A
(en)
*
|
1989-04-27 |
1996-11-19 |
The Salk Institute For Biological Studies |
Fibroblast growth factor conjugates
|
IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
EP0436005B1
(fr)
*
|
1989-07-20 |
1995-03-29 |
Sandoz Ltd. |
Derives de polypeptide etiquetes
|
US5208323A
(en)
*
|
1989-08-10 |
1993-05-04 |
Universite Laval |
Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
US5182107A
(en)
*
|
1989-09-07 |
1993-01-26 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US5632988A
(en)
*
|
1989-10-23 |
1997-05-27 |
Schering Corporation |
Polypeptide inhibitors of gamma interferon
|
CA2076678C
(fr)
*
|
1990-03-02 |
1999-09-28 |
Diane Williams |
Toxines chimeres ameliorees
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
US5137877B1
(en)
*
|
1990-05-14 |
1996-01-30 |
Bristol Myers Squibb Co |
Bifunctional linking compounds conjugates and methods for their production
|
DK0485563T3
(da)
*
|
1990-05-30 |
1995-03-20 |
Deutsches Krebsforsch |
Polyethersubstituerede antitumormidler
|
IL98528A0
(en)
*
|
1990-06-21 |
1992-07-15 |
Merck & Co Inc |
Pharmaceutical compositions containing hybrid for killing bladder cancer cells
|
CA2086679A1
(fr)
*
|
1990-07-05 |
1992-01-06 |
Hermanus A. M. Verheul |
Conjugues contenant une toxine dirigee contre un recepteur
|
US5478804A
(en)
*
|
1990-09-19 |
1995-12-26 |
The Salk Institute For Biological Studies |
Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
|
WO1992005802A1
(fr)
*
|
1990-09-28 |
1992-04-16 |
Neorx Corporation |
Porteurs polymeres servant a la liberation d'agents a liaison covalente
|
US5431899A
(en)
*
|
1991-02-04 |
1995-07-11 |
University Of Saskatchewan |
Rotavirus VP6 as a diagnostic and targeting agent
|
US5464753A
(en)
*
|
1991-03-08 |
1995-11-07 |
Univ Illinois |
Purification and manipulation of bone marrow and blood cells on the basis of P-glycoprotein expression
|
AU1674292A
(en)
*
|
1991-03-15 |
1992-10-21 |
Synergen, Inc. |
Pegylation of polypeptides
|
AU662155B2
(en)
*
|
1991-05-10 |
1995-08-24 |
Celtrix Pharmaceuticals, Inc. |
Targeted delivery of bone growth factors
|
EP0529175B1
(fr)
*
|
1991-07-22 |
1995-08-09 |
BRACCO International B.V. |
Conjugés chélatés aux métaux paramagnétiques, pour ciblage
|
US5981273A
(en)
*
|
1991-09-30 |
1999-11-09 |
Boehringer Ingelheim Int'l. Gmbh |
Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
|
NZ244306A
(en)
*
|
1991-09-30 |
1995-07-26 |
Boehringer Ingelheim Int |
Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
|
US5521291A
(en)
*
|
1991-09-30 |
1996-05-28 |
Boehringer Ingelheim International, Gmbh |
Conjugates for introducing nucleic acid into higher eucaryotic cells
|
US5922859A
(en)
*
|
1992-02-01 |
1999-07-13 |
Boehringer Ingelheim International Gmbh |
Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
|
CA2076465C
(fr)
*
|
1992-03-25 |
2002-11-26 |
Ravi V. J. Chari |
Conjugues agents de liaison cellulaire d'analogues et de derives de cc-1065
|
AU4394293A
(en)
*
|
1992-05-28 |
1993-12-30 |
University Of Toledo, The |
Delivery of a cytotoxic compound to a cancer cell using a pathway of plasminogen activator material
|
US5679350A
(en)
*
|
1992-05-28 |
1997-10-21 |
The University Of Toledo |
Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material
|
EP0646174A1
(fr)
*
|
1992-06-16 |
1995-04-05 |
The Whittier Institute For Diabetes And Endocrinology |
Production recombinee de proteines contenant de la saporine
|
US5393737A
(en)
*
|
1992-08-20 |
1995-02-28 |
Health Research, Inc. |
Cytotoxic drug conjugates for treatment of neoplastic diseases
|
WO1994005800A1
(fr)
*
|
1992-09-03 |
1994-03-17 |
The Regents Of The University Of California |
Facteur influant sur le tissu dorsal et compositions
|
US5466672A
(en)
*
|
1992-12-04 |
1995-11-14 |
Ophidian Pharmaceuticals, Inc. |
Therapeutic use of clostridium difficile toxin A
|
US6174530B1
(en)
|
1993-05-05 |
2001-01-16 |
Gryphon Sciences |
Homogeneous polyoxime compositions and their preparation by parallel assembly
|
US6001364A
(en)
*
|
1993-05-05 |
1999-12-14 |
Gryphon Sciences |
Hetero-polyoxime compounds and their preparation by parallel assembly
|
ES2146649T3
(es)
|
1993-05-05 |
2000-08-16 |
Keith Rose |
Compuestos de polioximas y su preparacion.
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
US5502037A
(en)
*
|
1993-07-09 |
1996-03-26 |
Neuromed Technologies, Inc. |
Pro-cytotoxic drug conjugates for anticancer therapy
|
US6491905B1
(en)
*
|
1993-09-14 |
2002-12-10 |
The Uab Research Foundation |
Recombinant bacterial cells for delivery of PNP to tumor cells
|
PT648503E
(pt)
*
|
1993-09-22 |
2000-11-30 |
Hoechst Ag |
Pro-profarmacos, sua producao e utilizacao
|
US5879656A
(en)
*
|
1993-10-26 |
1999-03-09 |
Thomas Jefferson University |
Methods of treating metastatic colorectal cancer with ST receptor binding compounds
|
US5962220A
(en)
*
|
1993-10-26 |
1999-10-05 |
Thomas Jefferson University |
Compositions that specifically bind to colorectal cells and methods of using the same
|
US7097839B1
(en)
|
1993-10-26 |
2006-08-29 |
Thomas Jefferson University |
ST receptor binding compounds and methods of using the same
|
DE69434279T2
(de)
*
|
1993-12-09 |
2006-04-06 |
Centro De Inmunologia Molecular |
Impfstoff, der einen menschlichen autologenen epidermalen Wachstumsfaktor enthält und dessen Verwendung
|
US6551618B2
(en)
*
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
US5911995A
(en)
*
|
1994-08-19 |
1999-06-15 |
Regents Of The University Of Minnesota |
EGF-genistein conjugates for the treatment of cancer
|
US5587459A
(en)
*
|
1994-08-19 |
1996-12-24 |
Regents Of The University Of Minnesota |
Immunoconjugates comprising tyrosine kinase inhibitors
|
DE4433890C2
(de)
*
|
1994-09-22 |
1999-02-18 |
Deutsches Krebsforsch |
Konjugat aus einem Wirkstoff und einem nicht als körperfremd angesehenen, nativen Protein
|
AU708529B2
(en)
*
|
1994-11-10 |
1999-08-05 |
University Of Kentucky Research Foundation, The |
Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
|
US5766899A
(en)
*
|
1995-02-27 |
1998-06-16 |
Board Of Regents , The University Of Texas System |
Targeted nucleic acid delivery into liver cells
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US20030119724A1
(en)
*
|
1995-11-22 |
2003-06-26 |
Ts`O Paul O.P. |
Ligands to enhance cellular uptake of biomolecules
|
PT871490E
(pt)
*
|
1995-12-22 |
2003-07-31 |
Bristol Myers Squibb Co |
Ligantes de hidrazona ramificada
|
US20050025740A1
(en)
*
|
1996-01-05 |
2005-02-03 |
Keith Rose |
Polyoxime compounds and their preparation
|
PL189698B1
(pl)
|
1996-03-12 |
2005-09-30 |
Pg Txl Co |
Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
|
US6441025B2
(en)
*
|
1996-03-12 |
2002-08-27 |
Pg-Txl Company, L.P. |
Water soluble paclitaxel derivatives
|
US6030941A
(en)
*
|
1996-05-01 |
2000-02-29 |
Avi Biopharma, Inc. |
Polymer composition for delivering substances in living organisms
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
US5952294A
(en)
*
|
1996-07-31 |
1999-09-14 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Peptidyl prodrugs and methods of making and using the same
|
DE19636889A1
(de)
|
1996-09-11 |
1998-03-12 |
Felix Dr Kratz |
Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
|
US6080383A
(en)
*
|
1997-01-13 |
2000-06-27 |
Rose; Samuel |
Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
|
WO1998047496A2
(fr)
*
|
1997-04-18 |
1998-10-29 |
Access Pharmaceuticals, Inc. |
Composes a base de polymere et de platine
|
US5965118A
(en)
*
|
1997-04-18 |
1999-10-12 |
Access Pharmaceuticals, Inc. |
Polymer-platinum compounds
|
US6916790B2
(en)
|
1997-05-05 |
2005-07-12 |
Mayo Foundation For Medical Education And Research |
Treatment of osteoporosis
|
EP0981545B1
(fr)
*
|
1997-05-05 |
2006-09-13 |
Mayo Foundation For Medical Education And Research |
Le complexe IGFIIE/ IGFBP2
|
US6548482B1
(en)
|
1997-05-05 |
2003-04-15 |
Mayo Foundation For Medical Education And Research |
Treatment of osteoporosis
|
US6030997A
(en)
*
|
1998-01-21 |
2000-02-29 |
Eilat; Eran |
Acid labile prodrugs
|
US6866837B2
(en)
|
1998-06-05 |
2005-03-15 |
Mallinckrodt Inc. |
Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors
|
AU764603B2
(en)
*
|
1998-07-17 |
2003-08-21 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services, The |
Water-soluble drugs and methods for their production
|
US6747055B1
(en)
*
|
1998-07-17 |
2004-06-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Water-soluble drugs and methods for their production
|
GB9904582D0
(en)
*
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
US7018654B2
(en)
*
|
1999-03-05 |
2006-03-28 |
New River Pharmaceuticals Inc. |
Pharmaceutical composition containing an active agent in an amino acid copolymer structure
|
US6716452B1
(en)
*
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US7060708B2
(en)
*
|
1999-03-10 |
2006-06-13 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US20010041189A1
(en)
*
|
1999-04-13 |
2001-11-15 |
Jingya Xu |
Poly(dipeptide) as a drug carrier
|
US6706892B1
(en)
|
1999-09-07 |
2004-03-16 |
Conjuchem, Inc. |
Pulmonary delivery for bioconjugation
|
US20030054977A1
(en)
*
|
1999-10-12 |
2003-03-20 |
Cell Therapeutics, Inc. |
Manufacture of polyglutamate-therapeutic agent conjugates
|
US7067111B1
(en)
*
|
1999-10-25 |
2006-06-27 |
Board Of Regents, University Of Texas System |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
US20020077290A1
(en)
*
|
2000-03-17 |
2002-06-20 |
Rama Bhatt |
Polyglutamic acid-camptothecin conjugates and methods of preparation
|
US20020012931A1
(en)
|
2000-03-27 |
2002-01-31 |
Waldman Scott A. |
High specificity marker detection
|
WO2001091807A2
(fr)
|
2000-06-02 |
2001-12-06 |
Board Of Regents |
Conjugues d'ethylenedicysteine (ec) et d'un medicament, compositions et procedes pour l'imagerie de maladies a specificite tissulaire
|
EP1297002A2
(fr)
*
|
2000-06-30 |
2003-04-02 |
Board Of Regents, The University Of Texas System |
Isolement d'un peptide d'internalisation specifique des cellules infiltrant les tissus tumoraux pour liberation medicamenteuse ciblee
|
US20020099013A1
(en)
*
|
2000-11-14 |
2002-07-25 |
Thomas Piccariello |
Active agent delivery systems and methods for protecting and administering active agents
|
US7163918B2
(en)
|
2000-08-22 |
2007-01-16 |
New River Pharmaceuticals Inc. |
Iodothyronine compositions
|
EP1333811A4
(fr)
*
|
2000-10-16 |
2004-03-03 |
Neopharm Inc |
Preparation liposomales a base de mitoxantrone
|
US8394813B2
(en)
*
|
2000-11-14 |
2013-03-12 |
Shire Llc |
Active agent delivery systems and methods for protecting and administering active agents
|
CN100406065C
(zh)
|
2000-12-01 |
2008-07-30 |
细胞工厂治疗公司 |
糖基化/半乳糖基化肽、双官能接头和核苷酸单体/多聚体的缀合物以及相关的组合物和使用方法
|
CU22999A1
(es)
|
2001-12-04 |
2004-10-12 |
Centro Inmunologia Molecular |
Método de tratamiento de enfermedades malignas e infecciosas crónicas
|
CA2444383A1
(fr)
*
|
2001-04-26 |
2002-11-07 |
Board Of Regents, The University Of Texas System |
Compositions therapeutiques conjuguees agent/ligand, leur methodes de synthese et leur utilisation
|
WO2002092771A2
(fr)
|
2001-05-11 |
2002-11-21 |
Ludwig Institute For Cancer Research |
Proteines de liaison specifiques et utilisations associees
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
CN100372566C
(zh)
*
|
2001-05-15 |
2008-03-05 |
福克医药公司 |
治疗病毒感染的靶向给药组合物及方法
|
US7001991B2
(en)
*
|
2001-05-15 |
2006-02-21 |
Faulk Pharmaceuticals, Inc. |
Targeted delivery of bioaffecting compounds for the treatment of cancer
|
CA2451511A1
(fr)
*
|
2001-06-22 |
2003-01-03 |
The University Of British Columbia |
Eleuthesides antimitotiques
|
US20060014697A1
(en)
*
|
2001-08-22 |
2006-01-19 |
Travis Mickle |
Pharmaceutical compositions for prevention of overdose or abuse
|
US7375082B2
(en)
*
|
2002-02-22 |
2008-05-20 |
Shire Llc |
Abuse-resistant hydrocodone compounds
|
US7338939B2
(en)
*
|
2003-09-30 |
2008-03-04 |
New River Pharmaceuticals Inc. |
Abuse-resistant hydrocodone compounds
|
US7169752B2
(en)
*
|
2003-09-30 |
2007-01-30 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US20070066537A1
(en)
*
|
2002-02-22 |
2007-03-22 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
WO2003072046A2
(fr)
*
|
2002-02-22 |
2003-09-04 |
New River Pharmaceuticals Inc. |
Nouveaux composes pharmaceutiques a liberation prolongee destines a empecher la consommation abusive de substances controlees
|
US20030109432A1
(en)
*
|
2001-12-10 |
2003-06-12 |
Zuo William W. |
Anticancer polypeptide-metal complexes and compositions, methods of making, and methods of using same
|
RU2196604C1
(ru)
*
|
2001-12-21 |
2003-01-20 |
Северин Евгений Сергеевич |
Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
|
US7261875B2
(en)
*
|
2001-12-21 |
2007-08-28 |
Board Of Regents, The University Of Texas System |
Dendritic poly (amino acid) carriers and methods of use
|
US7700561B2
(en)
*
|
2002-02-22 |
2010-04-20 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
US7105486B2
(en)
*
|
2002-02-22 |
2006-09-12 |
New River Pharmaceuticals Inc. |
Abuse-resistant amphetamine compounds
|
WO2003072735A2
(fr)
*
|
2002-02-22 |
2003-09-04 |
New River Pharmaceuticals Inc. |
Utilisation de la conjugaison peptide-medicament pour diminuer la variabilite entre sujets de niveaux de serum de medicament
|
US7659253B2
(en)
*
|
2002-02-22 |
2010-02-09 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
EP2316468A1
(fr)
|
2002-02-22 |
2011-05-04 |
Shire LLC |
Système de distribution et méthodes de protection et d'administration de dextroamphetamine
|
EP2422775A3
(fr)
|
2002-09-20 |
2012-04-18 |
Alpharma, Inc. |
Séquestration de sous-unité et compositions et procédés associés
|
EP1562641A4
(fr)
*
|
2002-11-07 |
2008-12-03 |
Univ Texas |
Conjugues ethylene dicysteine (ec)-medicament, compositions et procedes d'imagerie de maladies specifiques des tissus
|
CA2524350C
(fr)
|
2003-05-07 |
2015-04-14 |
Indiana University Research & Technology Corporation |
Points quantiques a alliage de semi-conducteurs et points quantiques a alliage a gradient de concentration, series comprenant ces points quantiques et procedes associes
|
CA2527646C
(fr)
*
|
2003-05-29 |
2011-08-23 |
New River Pharmaceuticals Inc. |
Composes d'amphetamine resistant aux abus
|
WO2005016368A2
(fr)
*
|
2003-08-19 |
2005-02-24 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Methode permettant d'induire la biomineralisation, methode permettant d'induire la regeneration osseuse et methodes associees
|
AU2004277400B2
(en)
*
|
2003-09-30 |
2009-01-22 |
Shire Llc |
Pharmaceutical compositions for prevention of overdose or abuse
|
WO2005040170A2
(fr)
|
2003-10-22 |
2005-05-06 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Derives de pyrrolobenzodiazepine, compositions comprenant ces derives et methodes s'y rapportant
|
EP1694325A4
(fr)
|
2003-12-03 |
2009-03-25 |
Univ New Jersey Med |
Procede pour empecher la survie des cellules retrovirales et la formation des retrovirus infectieux
|
US9050378B2
(en)
*
|
2003-12-10 |
2015-06-09 |
Board Of Regents, The University Of Texas System |
N2S2 chelate-targeting ligand conjugates
|
US8012463B2
(en)
*
|
2003-12-10 |
2011-09-06 |
Toudai Tlo, Ltd. |
Coordination complex of diaminocyclohexaneplatinum(II) with block copolymer containing poly(carboxylic acid) segment and antitumor agent comprising the same
|
JP5301152B2
(ja)
|
2004-04-07 |
2013-09-25 |
ライナット ニューロサイエンス コーポレイション |
神経成長因子アンタゴニストを投与することによって骨癌の疼痛を処置するための方法
|
US8454927B2
(en)
*
|
2004-08-04 |
2013-06-04 |
Crystalplex Corporation |
Alloyed semiconductor nanocrystals
|
US20060036084A1
(en)
*
|
2004-08-04 |
2006-02-16 |
Lianhua Qu |
Conglomerated semiconductor nanocrystals
|
AU2006255938B2
(en)
*
|
2005-06-09 |
2011-05-12 |
Nanocarrier Co., Ltd. |
Process for production of polymerized coordination compound of platinum complex
|
WO2007055902A1
(fr)
*
|
2005-11-03 |
2007-05-18 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Peptides immunogènes et méthodes d'emploi dans le traitement prophylactique et thérapeutique du cancer
|
DK1969031T3
(da)
|
2005-12-05 |
2009-09-14 |
Nitto Denko Corp |
Polyglutamat-aminosyre-konjugater og fremgangsmåder
|
US7820174B2
(en)
|
2006-02-24 |
2010-10-26 |
The United States Of America As Represented By The Department Of Health And Human Services |
T cell receptors and related materials and methods of use
|
US9107863B2
(en)
*
|
2006-03-27 |
2015-08-18 |
The Buck Institute For Age Reasearch |
Reagents and methods for cancer treatment and prevention
|
US8758723B2
(en)
|
2006-04-19 |
2014-06-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for cellular imaging and therapy
|
ES2622576T3
(es)
|
2006-06-19 |
2017-07-06 |
Alpharma Pharmaceuticals Llc |
Composiciones farmacéuticas
|
US8088379B2
(en)
*
|
2006-09-26 |
2012-01-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Modified T cell receptors and related materials and methods
|
US10925977B2
(en)
|
2006-10-05 |
2021-02-23 |
Ceil>Point, LLC |
Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
|
EP2431388A1
(fr)
|
2006-10-31 |
2012-03-21 |
Government of the United States of America, Represented by the Secretary, Department of Health and Human Services |
Polypeptides lissés et procédés d'utilisation
|
CA2674445C
(fr)
|
2007-01-12 |
2016-06-07 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Recepteurs de lymphocyte t specifiques au gp100 et materiaux apparentes et procedes d'utilisation
|
EP2126127B1
(fr)
*
|
2007-01-25 |
2016-09-28 |
Dana-Farber Cancer Institute, Inc. |
Utilisation d'anticorps anti-egfr dans le traitement de maladie mediee par des mutants de recepteur du facteur de croissance epidermique (egfr)
|
US20080181852A1
(en)
*
|
2007-01-29 |
2008-07-31 |
Nitto Denko Corporation |
Multi-functional Drug Carriers
|
CA2680854C
(fr)
|
2007-03-15 |
2017-02-14 |
Ludwig Institute For Cancer Research |
Procede de traitement utilisant des anticorps d'egfr et des inhibiteurs de src, et formulations en rapport
|
JP2010526159A
(ja)
*
|
2007-04-10 |
2010-07-29 |
日東電工株式会社 |
多機能性ポリグルタミン酸塩薬物担体
|
EP2155255B1
(fr)
*
|
2007-05-09 |
2013-08-14 |
Nitto Denko Corporation |
Compositions comprenant un composé hydrophobe et un conjugué polyamino acide
|
EP2155254B1
(fr)
*
|
2007-05-09 |
2012-11-28 |
Nitto Denko Corporation |
Polymères conjugués avec des médicaments à base de platine
|
WO2008141110A2
(fr)
*
|
2007-05-09 |
2008-11-20 |
Nitto Denko Corporation |
Conjugués de polyglutamate et conjugués de polyglutamate-amino acide contenant une pluralité de médicaments
|
CN108424454B
(zh)
|
2007-08-14 |
2022-05-31 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
AU2008292910A1
(en)
*
|
2007-08-31 |
2009-03-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compounds for inhibiting Wip1, prodrugs and compositions thereof, and related methods
|
MX2010009670A
(es)
*
|
2008-03-06 |
2010-09-22 |
Nitto Denko Corp |
Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer.
|
WO2010075303A1
(fr)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Facteurs d'épissage avec un domaine de liaison à l'arn de protéine puf et domaine effecteur d'épissage et leurs utilisations
|
WO2010075417A1
(fr)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Récepteur de lymphocytes t spécifique de la survivine dans le traitement du cancer
|
US8785601B2
(en)
|
2009-01-28 |
2014-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell receptors and related materials and methods of use
|
WO2010106544A1
(fr)
*
|
2009-03-16 |
2010-09-23 |
Rajah Vijay Kumar |
Procédé et appareil de nanoperméabilisation par résonance focalisée(forn)
|
CN102448482A
(zh)
|
2009-03-27 |
2012-05-09 |
范安德尔研究所 |
甲状旁腺素肽和甲状旁腺素相关蛋白肽及使用方法
|
US8603814B2
(en)
|
2009-07-20 |
2013-12-10 |
Rutgers The State University Of New Jersey |
Method of inhibiting nonsense-mediated mRNA decay
|
US9849146B2
(en)
|
2009-07-20 |
2017-12-26 |
Rutgers, The State University Of New Jersey |
Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
|
WO2011032099A1
(fr)
|
2009-09-11 |
2011-03-17 |
The Board Of Trustees Of The University Of Illinois |
Méthodes pour traiter un disfonctionnement diastolique et états associés
|
US20110076232A1
(en)
*
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
AU2010301042B2
(en)
|
2009-10-01 |
2014-03-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
|
EP2488637B1
(fr)
|
2009-10-16 |
2015-12-23 |
The University Of British Columbia |
Compositions d'inhibiteurs de phosphatase et d'homologue de tensine (pten), utilisations et procédés
|
US20120208762A1
(en)
|
2009-10-27 |
2012-08-16 |
The Board Of Trustees Of The University Of Illinois |
Methods of Diagnosing Diastolic Dysfunction
|
US20120251514A1
(en)
|
2009-11-13 |
2012-10-04 |
University Health Network |
Modulated programmed death ligand-1
|
WO2011075393A2
(fr)
|
2009-12-18 |
2011-06-23 |
Indiana University Research And Technology Corporation |
Co-agonistes du récepteur du glucagon/glp-i
|
JP2013518115A
(ja)
|
2010-01-27 |
2013-05-20 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐gipアゴニスト複合体及び組成物
|
EP2547359B1
(fr)
|
2010-03-15 |
2016-03-09 |
The Board of Trustees of the University of Illionis |
Inhibiteurs des interactions de liaison de sous unité alpha d'intégrine à-de protéine g
|
US9345748B2
(en)
|
2010-09-21 |
2016-05-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-SSX-2 T cell receptors and related materials and methods of use
|
WO2012054825A1
(fr)
|
2010-10-22 |
2012-04-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Récepteurs de lymphocytes t anti-mage-a3, matériaux associés et méthodes d'utilisation associées
|
WO2012087943A2
(fr)
|
2010-12-20 |
2012-06-28 |
The Regents Of The University Of Michigan |
Inhibiteurs de l'interaction de liaison entre le récepteur du facteur de croissance épidermique et la protéine de choc thermique 90
|
CN103458920B
(zh)
|
2010-12-22 |
2016-07-06 |
印第安那大学科技研究公司 |
表现出gip受体活性的胰高血糖素类似物
|
CN102675422B
(zh)
|
2011-03-15 |
2014-02-05 |
天津托普泰克生物科技有限公司 |
抗乙型肝炎病毒x蛋白多肽药物
|
EP2694549B1
(fr)
|
2011-04-08 |
2018-08-15 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Récepteurs d'antigène chimérique de variant iii du récepteur du facteur de croissance anti-épidermique et leur utilisation pour le traitement du cancer
|
CN102746378B
(zh)
|
2011-04-22 |
2014-10-22 |
天津托普泰克生物科技有限公司 |
抗脂肪酸合成酶多肽及其应用
|
MX2013014388A
(es)
|
2011-06-09 |
2014-08-21 |
Health |
Exotoxina a de pseudomonas con epitopos de linfocitos t y/o linfocitos b menos inmunogenicos.
|
RS56173B1
(sr)
|
2011-06-22 |
2017-11-30 |
Univ Indiana Res & Tech Corp |
Koagonisti receptora za glukagon/glp-1 receptora
|
SI2755997T1
(sl)
|
2011-09-15 |
2018-11-30 |
The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health |
T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage
|
EP2755993B1
(fr)
|
2011-09-16 |
2017-11-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Exotoxine a de pseudomonas des épitopes de cellules b moins immunogènes
|
WO2013059593A1
(fr)
|
2011-10-20 |
2013-04-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Récepteurs d'antigènes chimériques anti-cd22
|
RU2014117678A
(ru)
|
2011-11-17 |
2015-12-27 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
|
EP2828290B1
(fr)
|
2012-03-23 |
2018-08-15 |
The United States of America, represented by the Secretary, Department of Health and Human Services |
Récepteurs d'antigène chimérique anti-mésothéline
|
EA201990959A1
(ru)
|
2012-04-11 |
2020-02-10 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
|
CA2874486C
(fr)
|
2012-05-22 |
2021-08-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recepteurs murins des lymphocytes t anti-ny-eso-1
|
MX2014015205A
(es)
|
2012-06-14 |
2015-08-14 |
Ambrx Inc |
Anticuerpos anti-psma conjugados a polipeptidos de ligando de receptor nuclear.
|
KR20150023013A
(ko)
|
2012-06-21 |
2015-03-04 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
수용체 활성을 나타내는 글루카곤 유사체
|
TWI644920B
(zh)
|
2012-06-21 |
2018-12-21 |
美商印第安納大學科技研究公司 |
展現gip受體活性之胰高血糖素類似物
|
IL286786B
(en)
|
2012-09-14 |
2022-09-01 |
The Us Secretary Department Of Health And Human Services Office Of Technology Transfer National Inst |
T cell receptors that recognize mhc mage–a3 are restricted type ii
|
AU2013335180B2
(en)
|
2012-10-24 |
2018-07-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
M971 chimeric antigen receptors
|
US9790282B2
(en)
|
2013-03-25 |
2017-10-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
|
WO2014205187A1
(fr)
|
2013-06-20 |
2014-12-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Sous-unité b de toxine cytolétale distendante conjuguée ou fusionnée à un facteur létal de toxine de bacillus anthracis
|
US9822162B2
(en)
|
2013-07-15 |
2017-11-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-human papillomavirus 16 E6 T cell receptors
|
AU2014329437B2
(en)
|
2013-10-06 |
2018-10-18 |
F. Hoffmann-La Roche Ag |
Modified Pseudomonas exotoxin A
|
US10676528B2
(en)
|
2013-12-06 |
2020-06-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
|
RU2763795C2
(ru)
|
2014-04-23 |
2022-01-11 |
Джуно Терапьютикс, Инк. |
Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии
|
IL290655B1
(en)
|
2014-05-29 |
2024-01-01 |
Us Health |
Anti-human papillomavirus 16 E7 T-cell chelates
|
JP6797693B2
(ja)
|
2014-06-02 |
2020-12-09 |
アメリカ合衆国 |
Cd−19を標的とするキメラ抗原受容体
|
CN107075483A
(zh)
|
2014-07-15 |
2017-08-18 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗的工程改造的细胞
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
IL293714A
(en)
|
2014-10-20 |
2022-08-01 |
Juno Therapeutics Inc |
Methods and preparations for dosing in stress cell therapy
|
EP3215164A1
(fr)
|
2014-11-03 |
2017-09-13 |
Immures S.r.l. |
Récepteurs de lymphocytes t
|
PT3215601T
(pt)
|
2014-11-05 |
2020-08-03 |
Juno Therapeutics Inc |
Métodos de transdução e transformação de células
|
US11266739B2
(en)
|
2014-12-03 |
2022-03-08 |
Juno Therapeutics, Inc. |
Methods and compositions for adoptive cell therapy
|
CA2973964A1
(fr)
|
2015-01-16 |
2016-07-21 |
Juno Therapeutics, Inc. |
Anticorps et recepteurs antigeniques chimeriques specifiques de ror1
|
WO2016166568A1
(fr)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil permettant d'augmenter une population de cellules
|
MA43344A
(fr)
|
2015-05-29 |
2018-04-11 |
Juno Therapeutics Inc |
Composition et procédés de régulation des interactions inhibitrices dans les cellules génétiquement modifiées
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
AU2016341527B2
(en)
|
2015-10-22 |
2023-04-27 |
Juno Therapeutics Gmbh |
Methods, kits, agents and apparatuses for transduction
|
MA44314A
(fr)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
|
WO2017079703A1
(fr)
|
2015-11-05 |
2017-05-11 |
Juno Therapeutics, Inc. |
Vecteurs et cellules immunitaires génétiquement modifiées exprimant des modulateurs de voie métabolique et utilisations en thérapie cellulaire adoptive
|
MX2018006789A
(es)
|
2015-12-03 |
2019-02-13 |
Juno Therapeutics Inc |
Receptores quimericos modificados y composiciones y metodos relacionados.
|
WO2017096331A1
(fr)
|
2015-12-04 |
2017-06-08 |
Juno Therapeutics, Inc. |
Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
|
MA43758A
(fr)
|
2016-03-16 |
2018-11-28 |
Yuan Ji |
Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés
|
MA43759A
(fr)
|
2016-03-16 |
2018-11-28 |
Jason Connor |
Procédés de conception adaptative d'un régime de traitement et traitements associés
|
ES2907557T3
(es)
|
2016-03-22 |
2022-04-25 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Métodos de intervención temprana para prevenir o mejorar la toxicidad
|
IL262772B2
(en)
|
2016-05-06 |
2023-10-01 |
Juno Therapeutics Inc |
Genetically engineered cells and methods for their preparation
|
EP4011381A1
(fr)
|
2016-06-03 |
2022-06-15 |
Memorial Sloan-Kettering Cancer Center |
Thérapies cellulaires adoptives utilisées en tant qu'options de traitement précoce
|
MA45341A
(fr)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
|
CN110291402B
(zh)
|
2016-06-27 |
2023-09-01 |
朱诺治疗学股份有限公司 |
鉴定肽表位的方法、结合此类表位的分子和相关用途
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
WO2018005759A1
(fr)
|
2016-07-01 |
2018-01-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Inhibiteur de la dégradation de l'hème pour améliorer le traitement antibiotique de l'infection par mycobacterium tuberculosis.
|
EP3490585B1
(fr)
|
2016-07-29 |
2023-05-17 |
Juno Therapeutics, Inc. |
Polypeptides immunomdulateurs et compositions et procédés associés
|
CN110139873A
(zh)
|
2016-10-03 |
2019-08-16 |
朱诺治疗学股份有限公司 |
Hpv特异性结合分子
|
AU2017367695A1
(en)
|
2016-12-02 |
2019-06-13 |
Juno Therapeutics, Inc. |
Engineered B cells and related compositions and methods
|
AU2017368333A1
(en)
|
2016-12-03 |
2019-06-13 |
Juno Therapeutics, Inc. |
Methods for determining CAR-T cells dosing
|
WO2018102786A1
(fr)
|
2016-12-03 |
2018-06-07 |
Juno Therapeutics, Inc. |
Procédés de modulation de lymphocytes t modifiés par car
|
EP3548611A1
(fr)
|
2016-12-05 |
2019-10-09 |
Juno Therapeutics, Inc. |
Production de cellules modifiées pour une thérapie cellulaire adoptive
|
JP7429338B2
(ja)
|
2017-01-10 |
2024-02-08 |
ジュノー セラピューティクス インコーポレイテッド |
細胞療法および関連方法のエピジェネティック解析
|
AU2018209400B2
(en)
|
2017-01-20 |
2022-06-02 |
Juno Therapeutics Gmbh |
Cell surface conjugates and related cell compositions and methods
|
US11850262B2
(en)
|
2017-02-28 |
2023-12-26 |
Purdue Research Foundation |
Compositions and methods for CAR T cell therapy
|
AU2018250336A1
(en)
|
2017-04-07 |
2019-09-26 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
|
CN111032850A
(zh)
|
2017-04-27 |
2020-04-17 |
朱诺治疗学有限公司 |
寡聚粒子试剂及其使用方法
|
CA3065120A1
(fr)
|
2017-06-02 |
2018-12-06 |
Juno Therapeutics, Inc. |
Articles de fabrication et procedes de traitement utilisant une therapie cellulaire adoptive
|
CN111201438A
(zh)
|
2017-06-02 |
2020-05-26 |
朱诺治疗学股份有限公司 |
与和细胞疗法相关的毒性有关的制品和方法
|
CN109517820B
(zh)
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
一种靶向HPK1的gRNA以及HPK1基因编辑方法
|
MX2020003536A
(es)
|
2017-10-03 |
2020-09-14 |
Juno Therapeutics Inc |
Moleculas de union especifica a virus de papiloma humano (hpv).
|
CN111542596A
(zh)
|
2017-11-01 |
2020-08-14 |
朱诺治疗学股份有限公司 |
产生工程化细胞的治疗性组合物的方法
|
AU2018360800A1
(en)
|
2017-11-01 |
2020-05-14 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for B-cell maturation antigen (BCMA)
|
MX2020004239A
(es)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics Inc |
Proceso para producir una composicion de celulas t.
|
BR112020008478A2
(pt)
|
2017-11-01 |
2020-10-20 |
Editas Medicine, Inc. |
métodos, composições e componentes para edição de crispr-cas9 de tgfbr2 em células t para imunota-rapia
|
SG11202003501XA
(en)
|
2017-11-01 |
2020-05-28 |
Juno Therapeutics Inc |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
JP2021502077A
(ja)
|
2017-11-06 |
2021-01-28 |
エディタス・メディシン,インコーポレイテッド |
免疫療法のためのt細胞におけるcblbのcrispr−cas9編集のための方法、組成物および構成要素
|
KR20200116081A
(ko)
|
2017-12-01 |
2020-10-08 |
주노 쎄러퓨티크스 인코퍼레이티드 |
유전자 조작된 세포의 투약 및 조절 방법
|
MX2020005908A
(es)
|
2017-12-08 |
2020-10-07 |
Juno Therapeutics Inc |
Proceso para producir una composicion de celulas t modificadas.
|
CN112041430A
(zh)
|
2017-12-08 |
2020-12-04 |
朱诺治疗学股份有限公司 |
用于培养细胞的无血清培养基配制品及其使用方法
|
CN112203680A
(zh)
|
2017-12-08 |
2021-01-08 |
朱诺治疗学股份有限公司 |
用于细胞疗法的表型标记和相关方法
|
MA51184A
(fr)
|
2017-12-15 |
2020-10-21 |
Juno Therapeutics Inc |
Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
|
JP2021512147A
(ja)
|
2018-01-22 |
2021-05-13 |
エンドサイト・インコーポレイテッドEndocyte, Inc. |
Car t細胞の使用方法
|
US20210069246A1
(en)
|
2018-01-31 |
2021-03-11 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
WO2019170845A1
(fr)
|
2018-03-09 |
2019-09-12 |
Ospedale San Raffaele S.R.L. |
Antagoniste de l'il-1 et toxicité induite par la thérapie cellulaire
|
KR20210029707A
(ko)
|
2018-04-05 |
2021-03-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 세포의 생산 방법 및 관련 조성물
|
SG11202009284TA
(en)
|
2018-04-05 |
2020-10-29 |
Juno Therapeutics Inc |
T cell receptors and engineered cells expressing same
|
CA3095084A1
(fr)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
Lymphocytes t exprimant un recepteur recombinant, polynucleotides et procedes associes
|
KR20210057730A
(ko)
|
2018-08-09 |
2021-05-21 |
주노 쎄러퓨티크스 인코퍼레이티드 |
조작 세포 및 이의 조성물 생성 방법
|
SG11202101130VA
(en)
|
2018-08-09 |
2021-03-30 |
Juno Therapeutics Inc |
Methods for assessing integrated nucleic acids
|
CA3110905A1
(fr)
|
2018-08-31 |
2020-03-05 |
Invectys SA |
Recepteurs d'antigenes chimeriques contre de multiples isoformes de hla-g
|
CN113227358A
(zh)
|
2018-10-31 |
2021-08-06 |
朱诺治疗学有限公司 |
选择并刺激细胞的方法及用于所述方法的设备
|
PE20211058A1
(es)
|
2018-11-01 |
2021-06-07 |
Juno Therapeutics Inc |
Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d)
|
CN113646335A
(zh)
|
2018-11-01 |
2021-11-12 |
朱诺治疗学股份有限公司 |
使用对b细胞成熟抗原具有特异性的嵌合抗原受体的治疗的方法
|
CA3117720A1
(fr)
|
2018-11-06 |
2020-05-14 |
Juno Therapeutics, Inc. |
Procede de production de cellules t genetiquement modifiees
|
MX2021005734A
(es)
|
2018-11-16 |
2021-09-10 |
Juno Therapeutics Inc |
Metodos de dosificacion de celulas t modificadas para el tratamiento de malignidades de celulas b.
|
AU2019387494A1
(en)
|
2018-11-30 |
2021-06-10 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment of B cell malignancies in adoptive cell therapy
|
JP2022513685A
(ja)
|
2018-11-30 |
2022-02-09 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法を用いた処置のための方法
|
US20220096651A1
(en)
|
2019-01-29 |
2022-03-31 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
CA3136618A1
(fr)
|
2019-04-10 |
2020-10-15 |
Elevatebio Technologies, Inc. |
Recepteurs antigeniques chimeriques specifiques de flt3 et leurs procedes d'utilisation
|
KR20220016475A
(ko)
|
2019-05-01 |
2022-02-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
변형된 tgfbr2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법
|
US20220218750A1
(en)
|
2019-05-01 |
2022-07-14 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
IL288284B1
(en)
|
2019-05-22 |
2024-02-01 |
Massachusetts Inst Technology |
Circular Rana preparations and methods
|
CN112390894A
(zh)
|
2019-08-12 |
2021-02-23 |
广东东阳光药业有限公司 |
嵌合抗原受体及其应用
|
JP2023500318A
(ja)
|
2019-10-30 |
2023-01-05 |
ジュノ セラピューティクス ゲーエムベーハー |
細胞選択および/または細胞刺激デバイスならびに使用方法
|
WO2021113770A1
(fr)
|
2019-12-06 |
2021-06-10 |
Juno Therapeutics, Inc. |
Procédés liés à la toxicité et à la réponse associées à une thérapie cellulaire pour le traitement de tumeurs malignes des lymphocytes b
|
US20230090117A1
(en)
|
2020-01-28 |
2023-03-23 |
Juno Therapeutics, Inc. |
Methods for t cell transduction
|
WO2021207689A2
(fr)
|
2020-04-10 |
2021-10-14 |
Juno Therapeutics, Inc. |
Méthodes et utilisations associées à une thérapie cellulaire modifiée à l'aide d'un récepteur antigénique chimérique ciblant un antigène de maturation des lymphocytes b
|
CN115803824A
(zh)
|
2020-05-13 |
2023-03-14 |
朱诺治疗学股份有限公司 |
鉴定与临床反应相关的特征的方法及其用途
|
CA3179423A1
(fr)
|
2020-05-19 |
2021-11-25 |
Robert Alexander WESSELHOEFT |
Methodes et compositions d'arn circulaire
|
JP2023531531A
(ja)
|
2020-06-26 |
2023-07-24 |
ジュノ セラピューティクス ゲーエムベーハー |
組換え受容体を条件付きで発現する操作されたt細胞、関連ポリヌクレオチド、および方法
|
JP2023549780A
(ja)
|
2020-11-04 |
2023-11-29 |
ジュノー セラピューティクス インコーポレイテッド |
改変されたインバリアントcd3免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
|
KR20230159851A
(ko)
|
2021-03-22 |
2023-11-22 |
주노 쎄러퓨티크스 인코퍼레이티드 |
치료 세포 조성물의 효력을 결정하는 방법
|
EP4334341A2
(fr)
|
2021-05-06 |
2024-03-13 |
Juno Therapeutics GmbH |
Méthodes de stimulation et de transduction de lymphocytes t
|
CN115404240A
(zh)
|
2021-05-28 |
2022-11-29 |
上海环码生物医药有限公司 |
制备环形rna的构建体、方法及其用途
|
WO2023081735A1
(fr)
|
2021-11-03 |
2023-05-11 |
Celgene Corporation |
Récepteurs antigéniques chimériques spécifiques de l'antigène de maturation des cellules b destinés à être utilisés dans le traitement d'un myélome
|
WO2023081526A1
(fr)
|
2021-11-08 |
2023-05-11 |
Orna Therapeutics, Inc. |
Compositions de nanoparticules lipidiques pour l'administration de polynucléotides circulaires
|
WO2023081900A1
(fr)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Lymphocytes t modifiés exprimant un récepteur recombiné de lymphocytes t (tcr) et systèmes et procédés apparentés
|
WO2023164440A1
(fr)
|
2022-02-22 |
2023-08-31 |
Juno Therapeutics, Inc. |
Lymphocytes t de récepteur d'auto-anticorps chimérique de protéinase 3 (pr3) et méthodes et utilisations associées
|
WO2023220655A1
(fr)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Méthodes pour surmonter la résistance aux médicaments par ré-sensibilisation de cellules cancéreuses à un traitement avec une thérapie antérieure par l'intermédiaire d'un traitement avec une thérapie par lymphocytes t
|
WO2023230548A1
(fr)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Procédé de prédiction d'une réponse à une thérapie par lymphocyte t
|
WO2023231959A2
(fr)
|
2022-05-30 |
2023-12-07 |
Shanghai Circode Biomed Co., Ltd |
Compositions d'arn circulaire synthétiques et leurs procédés d'utilisation
|
WO2023250400A1
(fr)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Méthodes de traitement pour thérapie de deuxième ligne par cellules car-t ciblées par cd19
|
WO2024006960A1
(fr)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Nanoparticules lipidiques pour l'administration d'acides nucléiques
|
US20240041929A1
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|